Full-Time

Associate Director

Toxicology & Biocompatibility, R&D, Medtech Surgery

Deadline 8/27/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$137k - $235.8k/yr

Bridgewater Township, NJ, USA

Hybrid

Three days on-site per week required.

Master's, PhD

Category
Biology & Biotech (1)

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • MS or Ph.D. in Toxicology, Pharmacology, Biological Sciences, or a related field required
  • A minimum of 4 years of experience in leading teams of technical subject matter experts, shaping operational changes, and navigating complexity to build new capabilities
  • A minimum of 8-10 years of experience in toxicology and biocompatibility assessments and evaluation in a medical device and/or pharmaceutical company, or similar combination of professional training and multi-year experience in the industry is required. Experience in medical devices is strongly preferred
  • Demonstrated working knowledge and expertise in conducting toxicological safety assessments for chemicals and transforming risk assessment into regulatory submission documents
  • A proven history of interaction with US FDA and other OUS regulatory authorities on implementation of ISO 10993, ISO 14971, and ISO 13485
  • Experience in absorbable biomaterials for implantable medical devices, including experience in medical device material degradation and toxicokinetics, is required
  • Familiarity with relevant industry standards, i.e., ISO 13485, ISO 10993, ISO 14971, and design control systems is required
  • Experience in leading and implementing process developments is required. Experience working in a regulated environment of medical device safety and supporting product submission and audit is required; support for worldwide market registration is preferred
  • Travel – up to 10%
  • Interpersonal and communication skills including collaboration with cross-functional teams and ability to present scientific data to diverse audiences
  • Strong critical thinking skills and the ability to analyze complex data to inform decision-making
  • Excellent written and verbal communication skills
  • Adequate to travel ability and willingness to work in a regulated environment
  • Ability to work across internal and external stakeholders to review product documentation and coordinate biocompatibility test strategies
  • Ability to lead and mentor teams of technical SMEs
  • Initiative-taking and self-directed performance in an unsupervised environment and tenacity to overcome major obstacles
  • Ability to drive problem resolution through analytical and problem-solving skills
  • Ability to participate in continuous improvement activities and shape processes and procedures
  • Responsible for complying with health, safety, and environmental practices and company regulations
  • Presents regulatory submissions and documentation as required
  • Ability to work in hybrid environment with flexibility to travel as needed
  • Ability to interact with notified bodies and regulatory representatives when needed
  • Excellent leadership and management skills
  • Ability to manage budgets and strategic plans
  • Experience in automated data systems development is preferred
  • Experience with biosafety laboratories and GLP familiarity are implied by job scope
  • Knowledge of ISO 10993, ISO 13485, ISO 14971

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
  • TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
  • The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.

What critics are saying

  • Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
  • The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
  • A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.

What makes Johnson & Johnson unique

  • J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
  • TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
  • TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 21st, 2026
J&J's TECVAYLI plus daratumumab approved in Europe for relapsed/refractory multiple myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.

Yahoo Finance
Aug 20th, 2026
J&J CEO signals double-digit growth by decade's end on new drug launches

Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.

Yahoo Finance
Aug 19th, 2026
Johnson & Johnson rises 57% in 12 months with near-zero correlation to S&P 500

Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.

Highly Capitalized
Aug 19th, 2026
J&J leads Delix's $85M Series C with right of first negotiation on neuroplasticity drug

Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.

Psychedelic Alpha
Aug 18th, 2026
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.